Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 19 | 2023 | 362 | 3.930 |
Why?
|
| Enterobacteriaceae | 8 | 2020 | 42 | 3.800 |
Why?
|
| Enterobacteriaceae Infections | 8 | 2020 | 48 | 3.780 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 10 | 2020 | 59 | 3.170 |
Why?
|
| beta-Lactamases | 11 | 2023 | 77 | 2.900 |
Why?
|
| Child | 27 | 2023 | 1326 | 2.050 |
Why?
|
| Child, Preschool | 20 | 2023 | 652 | 1.810 |
Why?
|
| Carbapenems | 5 | 2019 | 34 | 1.730 |
Why?
|
| Infant | 19 | 2021 | 541 | 1.550 |
Why?
|
| Adolescent | 20 | 2022 | 2172 | 1.400 |
Why?
|
| Bacterial Proteins | 8 | 2021 | 72 | 1.270 |
Why?
|
| Infant, Newborn | 16 | 2021 | 563 | 1.200 |
Why?
|
| Cross Infection | 4 | 2023 | 274 | 1.100 |
Why?
|
| Genotype | 2 | 2019 | 350 | 1.060 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2023 | 80 | 1.030 |
Why?
|
| Humans | 49 | 2023 | 26260 | 1.000 |
Why?
|
| Plasmids | 3 | 2023 | 44 | 0.990 |
Why?
|
| Chicago | 9 | 2021 | 857 | 0.910 |
Why?
|
| Escherichia coli | 2 | 2023 | 52 | 0.890 |
Why?
|
| Klebsiella pneumoniae | 3 | 2019 | 56 | 0.880 |
Why?
|
| Fluoroquinolones | 2 | 2023 | 15 | 0.870 |
Why?
|
| Case-Control Studies | 6 | 2023 | 567 | 0.830 |
Why?
|
| Endocarditis, Bacterial | 2 | 2016 | 8 | 0.810 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 68 | 0.810 |
Why?
|
| Prevalence | 5 | 2020 | 441 | 0.800 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2019 | 14 | 0.800 |
Why?
|
| Klebsiella Infections | 2 | 2019 | 51 | 0.750 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2021 | 3 | 0.740 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2021 | 4 | 0.740 |
Why?
|
| Staphylococcal Infections | 3 | 2015 | 155 | 0.740 |
Why?
|
| Myocarditis | 1 | 2021 | 11 | 0.730 |
Why?
|
| Gammaproteobacteria | 1 | 2021 | 4 | 0.730 |
Why?
|
| Bacterial Infections | 1 | 2021 | 47 | 0.700 |
Why?
|
| Pseudomonas Infections | 2 | 2017 | 46 | 0.690 |
Why?
|
| Fresh Water | 1 | 2020 | 5 | 0.690 |
Why?
|
| United States | 12 | 2022 | 2043 | 0.670 |
Why?
|
| Acinetobacter baumannii | 1 | 2019 | 5 | 0.650 |
Why?
|
| Acinetobacter Infections | 1 | 2019 | 6 | 0.650 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 13 | 0.620 |
Why?
|
| Male | 20 | 2021 | 14168 | 0.620 |
Why?
|
| Molecular Typing | 2 | 2019 | 10 | 0.600 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2021 | 47 | 0.590 |
Why?
|
| Risk Factors | 7 | 2021 | 2221 | 0.570 |
Why?
|
| Bacteria | 1 | 2018 | 69 | 0.570 |
Why?
|
| Ceftriaxone | 1 | 2017 | 5 | 0.550 |
Why?
|
| Evolution, Molecular | 1 | 2017 | 8 | 0.550 |
Why?
|
| beta-Lactam Resistance | 2 | 2017 | 11 | 0.550 |
Why?
|
| Raltegravir Potassium | 1 | 2016 | 1 | 0.540 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2016 | 3 | 0.540 |
Why?
|
| Eosinophilia | 1 | 2016 | 35 | 0.530 |
Why?
|
| Coxiella burnetii | 1 | 2016 | 3 | 0.520 |
Why?
|
| Q Fever | 1 | 2016 | 5 | 0.520 |
Why?
|
| Multilocus Sequence Typing | 4 | 2023 | 15 | 0.510 |
Why?
|
| Gingivitis, Necrotizing Ulcerative | 1 | 2015 | 1 | 0.500 |
Why?
|
| Pandemics | 4 | 2021 | 240 | 0.500 |
Why?
|
| Osteosarcoma | 1 | 2015 | 34 | 0.490 |
Why?
|
| Female | 18 | 2021 | 14520 | 0.480 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 116 | 0.450 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 2 | 0.440 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 3 | 0.440 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 5 | 0.440 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 8 | 0.440 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 64 | 0.420 |
Why?
|
| Pneumonia, Ventilator-Associated | 3 | 2018 | 21 | 0.420 |
Why?
|
| Molecular Epidemiology | 3 | 2021 | 28 | 0.420 |
Why?
|
| Pseudomonas aeruginosa | 4 | 2020 | 60 | 0.400 |
Why?
|
| Rheumatic Fever | 1 | 2012 | 3 | 0.390 |
Why?
|
| Macrolides | 1 | 2012 | 4 | 0.390 |
Why?
|
| Streptococcus pyogenes | 1 | 2012 | 4 | 0.390 |
Why?
|
| Pharyngitis | 1 | 2012 | 7 | 0.390 |
Why?
|
| Brucella | 1 | 2011 | 3 | 0.380 |
Why?
|
| Brucellosis | 1 | 2011 | 4 | 0.380 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 147 | 0.370 |
Why?
|
| Bacteremia | 1 | 2011 | 97 | 0.350 |
Why?
|
| Intensive Care Units | 3 | 2018 | 298 | 0.340 |
Why?
|
| DNA, Bacterial | 3 | 2019 | 41 | 0.320 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 65 | 0.310 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 343 | 0.310 |
Why?
|
| Young Adult | 4 | 2019 | 1948 | 0.310 |
Why?
|
| Leadership | 4 | 2021 | 104 | 0.300 |
Why?
|
| Staphylococcaceae | 1 | 2008 | 1 | 0.300 |
Why?
|
| Tuberculosis | 1 | 2007 | 20 | 0.280 |
Why?
|
| Public Health | 2 | 2018 | 68 | 0.270 |
Why?
|
| Pilot Projects | 2 | 2020 | 397 | 0.250 |
Why?
|
| Adult | 5 | 2022 | 7516 | 0.250 |
Why?
|
| Health Facilities | 2 | 2022 | 20 | 0.240 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 13 | 0.230 |
Why?
|
| Pneumonia | 2 | 2015 | 72 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2021 | 3283 | 0.220 |
Why?
|
| Phylogeny | 1 | 2023 | 40 | 0.220 |
Why?
|
| Antimicrobial Stewardship | 2 | 2020 | 11 | 0.220 |
Why?
|
| Respiration, Artificial | 3 | 2018 | 111 | 0.200 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2017 | 14 | 0.200 |
Why?
|
| Neutropenia | 1 | 2021 | 16 | 0.190 |
Why?
|
| Tachycardia | 1 | 2021 | 9 | 0.180 |
Why?
|
| Minority Groups | 1 | 2022 | 78 | 0.180 |
Why?
|
| Overweight | 1 | 2022 | 72 | 0.180 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 19 | 0.180 |
Why?
|
| Hypotension | 1 | 2021 | 28 | 0.180 |
Why?
|
| Bradycardia | 1 | 2021 | 22 | 0.180 |
Why?
|
| Logistic Models | 2 | 2019 | 353 | 0.180 |
Why?
|
| Mandatory Programs | 1 | 2021 | 2 | 0.180 |
Why?
|
| State Government | 1 | 2021 | 7 | 0.180 |
Why?
|
| Federal Government | 1 | 2021 | 4 | 0.180 |
Why?
|
| Masks | 1 | 2021 | 6 | 0.180 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 27 | 0.180 |
Why?
|
| Local Government | 1 | 2021 | 6 | 0.180 |
Why?
|
| Fever | 1 | 2021 | 34 | 0.180 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 279 | 0.180 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 2 | 0.180 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 68 | 0.180 |
Why?
|
| Clostridium Infections | 1 | 2020 | 22 | 0.180 |
Why?
|
| Candida | 1 | 2020 | 11 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2021 | 66 | 0.180 |
Why?
|
| Candidiasis | 1 | 2020 | 19 | 0.180 |
Why?
|
| Universal Precautions | 1 | 2020 | 3 | 0.180 |
Why?
|
| Siderophores | 1 | 2020 | 1 | 0.180 |
Why?
|
| Lactams | 1 | 2020 | 4 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2020 | 23 | 0.170 |
Why?
|
| Waste Disposal, Fluid | 1 | 2020 | 4 | 0.170 |
Why?
|
| Water Microbiology | 1 | 2020 | 10 | 0.170 |
Why?
|
| Escherichia coli Proteins | 1 | 2020 | 9 | 0.170 |
Why?
|
| Survivors | 1 | 2020 | 63 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 25 | 0.170 |
Why?
|
| Cephalosporins | 1 | 2019 | 13 | 0.160 |
Why?
|
| Obesity | 1 | 2022 | 299 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 1722 | 0.150 |
Why?
|
| Infection Control | 2 | 2022 | 162 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 875 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 80 | 0.150 |
Why?
|
| Regression Analysis | 1 | 2019 | 249 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 84 | 0.150 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2018 | 3 | 0.150 |
Why?
|
| Gram-Positive Bacteria | 1 | 2018 | 13 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2019 | 315 | 0.140 |
Why?
|
| Pregnancy | 2 | 2021 | 312 | 0.140 |
Why?
|
| Greece | 1 | 2017 | 2 | 0.140 |
Why?
|
| Latin America | 1 | 2017 | 5 | 0.140 |
Why?
|
| Israel | 1 | 2017 | 16 | 0.140 |
Why?
|
| Bilirubin | 1 | 2017 | 10 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 21 | 0.140 |
Why?
|
| Animals | 5 | 2020 | 3551 | 0.140 |
Why?
|
| Drug Eruptions | 1 | 2016 | 8 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 57 | 0.130 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2016 | 6 | 0.130 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 20 | 0.130 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 16 | 0.130 |
Why?
|
| Ventilators, Mechanical | 1 | 2016 | 22 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 94 | 0.130 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2015 | 5 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 92 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 43 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2015 | 76 | 0.120 |
Why?
|
| ADP Ribose Transferases | 1 | 2014 | 5 | 0.120 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 15 | 0.110 |
Why?
|
| Phagocytosis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Critical Illness | 1 | 2015 | 133 | 0.110 |
Why?
|
| Enterovirus B, Human | 1 | 2013 | 2 | 0.110 |
Why?
|
| Ampicillin | 1 | 2013 | 5 | 0.110 |
Why?
|
| Gentamicins | 1 | 2013 | 16 | 0.110 |
Why?
|
| Pregnant Women | 1 | 2013 | 14 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 117 | 0.110 |
Why?
|
| Carrier State | 1 | 2013 | 53 | 0.110 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 11 | 0.110 |
Why?
|
| Virulence Factors | 1 | 2013 | 9 | 0.110 |
Why?
|
| Time Factors | 2 | 2013 | 1347 | 0.100 |
Why?
|
| Urban Population | 1 | 2013 | 144 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 124 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2016 | 1665 | 0.100 |
Why?
|
| Ethylenediamines | 1 | 2012 | 5 | 0.100 |
Why?
|
| Hospital Mortality | 3 | 2018 | 130 | 0.100 |
Why?
|
| Penicillins | 1 | 2012 | 9 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 9 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2016 | 1801 | 0.100 |
Why?
|
| Splenomegaly | 1 | 2011 | 5 | 0.100 |
Why?
|
| Mexico | 1 | 2011 | 16 | 0.100 |
Why?
|
| Milk | 1 | 2011 | 13 | 0.100 |
Why?
|
| Hepatomegaly | 1 | 2011 | 7 | 0.090 |
Why?
|
| Travel | 1 | 2011 | 13 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2012 | 158 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 190 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 169 | 0.090 |
Why?
|
| Recurrence | 1 | 2011 | 288 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2012 | 592 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 853 | 0.080 |
Why?
|
| Mice | 3 | 2020 | 1380 | 0.070 |
Why?
|
| Failure to Thrive | 1 | 2007 | 2 | 0.070 |
Why?
|
| Antitubercular Agents | 1 | 2007 | 11 | 0.070 |
Why?
|
| Hospitals | 2 | 2018 | 149 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2015 | 3285 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 600 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 101 | 0.050 |
Why?
|
| Child Care | 1 | 2021 | 2 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 7 | 0.050 |
Why?
|
| Forecasting | 1 | 2021 | 97 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 6 | 0.040 |
Why?
|
| Transitional Care | 1 | 2020 | 4 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2020 | 29 | 0.040 |
Why?
|
| Research | 1 | 2020 | 40 | 0.040 |
Why?
|
| Blood-Borne Pathogens | 1 | 2020 | 4 | 0.040 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2020 | 1 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 1 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 11 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 30 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 11 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 11 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 50 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 25 | 0.040 |
Why?
|
| Binding Sites | 1 | 2020 | 62 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 116 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 40 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 142 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 162 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 70 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 170 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 294 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2017 | 247 | 0.030 |
Why?
|
| Integrons | 1 | 2016 | 2 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 56 | 0.030 |
Why?
|
| Maryland | 1 | 2016 | 7 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 321 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 107 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 103 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 290 | 0.030 |
Why?
|
| Illinois | 1 | 2015 | 223 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 53 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 161 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2013 | 1 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 242 | 0.030 |
Why?
|